ALK-Abello unveils multi-year plan to 'succeed in North America'

4 December 2017

Danish allergy immunotherapy (AIT) specialist ALK-Abello (ALKB: DC) has announced a three-year investment plan in a bid to become a global presence in allergy and allergic asthma.

In a statement, ALK said the impact of the strategic plan would subdue earnings over the next three years, although it expects efficiencies to offset the effect. Financial guidance is unchanged for 2017.

The company says it will invest approximately 1 billion Danish kroner ($160 million) to “succeed in North America,” noting that “current industry dynamics offer ALK a unique window of opportunity,” based around shared interests with allergists.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK